Walsh: Fed Should Gradually Reduce Forward Guidance
On April 21, Fed Chair nominee Walsh stated that the Federal Reserve should reduce its reliance on forward guidance and warned that excessive transparency could hinder policy flexibility when circumstances change. He remarked, "The Fed reveals to the world... what their predictions will be," but noted that "the Fed clings to its predictions for too long," a phenomenon related to the Fed's delayed response to soaring inflation during the pandemic from 2021 to 2022. In his view, reducing commitments would facilitate more flexible decision-making, as "if the Fed waits until meetings to make decisions, this gradual assessment process can help the central bank avoid repeated mistakes." He sees this as part of a broader reform agenda and added, "I believe these changes are very necessary, and if confirmed, I look forward to implementing them."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

